- $2.23bn
- $2.12bn
- $197.52m
Annual income statement for Vericel, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 118 | 124 | 156 | 164 | 198 |
Cost of Revenue | |||||
Gross Profit | 80.3 | 84.2 | 106 | 110 | 136 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 129 | 122 | 164 | 181 | 204 |
Operating Profit | -11.3 | 2.37 | -7.85 | -17.1 | -6.46 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.66 | 3.04 | -7.58 | -16 | -2.37 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.66 | 2.86 | -7.47 | -16.7 | -3.18 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.66 | 2.86 | -7.47 | -16.7 | -3.18 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.66 | 2.86 | -7.47 | -16.7 | -3.18 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.219 | 0.061 | -0.161 | -0.355 | -0.067 |